Aktie A2QQYS PSYBIO THERAPEUTICS CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen PsyBio Therapeutics Corp.

Aktien

A2QQYS

CA6936971044

PSYB.H

Verzögert Toronto S.E.
Andere Börsenplätze
 05:24:13 29.03.2024 		% 5 Tage % 1. Jan.
0,01 CAD -.--% Intraday Chart für PsyBio Therapeutics Corp. -.--% -.--%
2021 PsyBio Therapeutics meldet neue psychedelische Zusammensetzungen und Behandlungsmethoden zum Patent beim USPTO an MT
2021 PsyBio stärkt Führungsteam mit der Ernennung von Dr. Michael Spigarelli zum Chief Medical Officer MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie
PsyBio Therapeutics Corp. Announces Executive Changes
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer
PsyBio Therapeutics Announces Retention of Market Maker
PSYO THER : PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization
PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QQYS Aktie
  4. Nachrichten PsyBio Therapeutics Corp.
  5. Andere Sprachen